BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thompson MA, Hallmeyer S, Fitzpatrick VE, Liao Y, Mullane MP, Medlin SC, Copeland K, Weese JL. Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies. J Patient Cent Res Rev 2022;9:149-57. [PMID: 35935520 DOI: 10.17294/2330-0698.1952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Uaprasert N, Pitakkitnukun P, Tangcheewinsirikul N, Chiasakul T, Rojnuckarin P. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. Blood Cancer J 2022;12:173. [PMID: 36550105 DOI: 10.1038/s41408-022-00776-5] [Reference Citation Analysis]
2 Wang L, Wang W, Xu R, Berger NA. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care. Best Pract Res Clin Haematol 2022;35:101384. [PMID: 36494154 DOI: 10.1016/j.beha.2022.101384] [Reference Citation Analysis]